Radiopharmaceuticals for Persistent or Recurrent Uterine Cervix Cancer

Radiopharmaceuticals for Persistent or Recurrent Uterine Cervix Cancer

Uterine cervix cancers pose therapeutic challenges because of an overactive ribonucleotide reductase, which provides on-demand deoxyribonucleotides for DNA replication or for a DNA damage repair response. Ribonucleotide reductase overactivity bestows cancer cell resistance to the effects of radiothe...

Full description

Bibliographic Details
Main Authors: Charles A. Kunos, Jacek Capala, Elise C. Kohn, Susan Percy Ivy
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-06-01
Series:Frontiers in Oncology
Subjects:
radiopharmaceutical
targeted radioisotope therapy
uterine cervix cancer
cervical cancer
National Cancer Institute (NCI)
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00560/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.00560/full

Similar Items